GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (FRA:S3H) » Definitions » Net Current Asset Value

Acino Holding AG (FRA:S3H) Net Current Asset Value : €-16.56 (As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Acino Holding AG Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Acino Holding AG's net current asset value per share for the quarter that ended in Dec. 2013 was €-16.56.

The historical rank and industry rank for Acino Holding AG's Net Current Asset Value or its related term are showing as below:

FRA:S3H's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.15
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

Acino Holding AG Net Current Asset Value Historical Data

The historical data trend for Acino Holding AG's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acino Holding AG Net Current Asset Value Chart

Acino Holding AG Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.12 -1.05 -4.27 -22.65 -16.56

Acino Holding AG Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 2.12 -1.05 -4.27 -22.65 -16.56

Competitive Comparison of Acino Holding AG's Net Current Asset Value

For the Drug Manufacturers - General subindustry, Acino Holding AG's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acino Holding AG's Price-to-Net-Current-Asset-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Acino Holding AG's Price-to-Net-Current-Asset-Value falls into.



Acino Holding AG Net Current Asset Value Calculation

Acino Holding AG's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2013 is calculated as

Net Current Asset Value Per Share(A: Dec. 2013 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(127.678-184.98-0-0)/3.46
=-16.56

Acino Holding AG's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2013 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2013 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(127.678-184.98-0-0)/3.46
=-16.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acino Holding AG  (FRA:S3H) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Acino Holding AG Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Acino Holding AG's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Acino Holding AG (FRA:S3H) Business Description

Traded in Other Exchanges
N/A
Address
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.

Acino Holding AG (FRA:S3H) Headlines

No Headlines